Scarica l'app Stockscreener
3.17
1.25%
-0.04
Dopo l'orario di chiusura:
3.15
-0.02
-0.63%
Precedente Chiudi:
$3.21
Aprire:
$3.21
Volume 24 ore:
83,608
Relative Volume:
0.10
Capitalizzazione di mercato:
$7.24M
Reddito:
$75,700
Utile/perdita netta:
$-7.23M
Rapporto P/E:
-0.1842
EPS:
-17.2081
Flusso di cassa netto:
$-7.37M
1 W Prestazione:
-10.96%
1M Prestazione:
-4.80%
6M Prestazione:
-64.58%
1 anno Prestazione:
-68.30%
Intervallo 1D:
$3.04
$3.42
Intervallo di 1 settimana:
$2.97
$3.94
Portata 52W:
$2.3401
$12.03
Aclarion Inc Stock (ACON) Company Profile
Nome
Aclarion Inc
Settore
Industria
Telefono
833 275 2266
Indirizzo
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, TEM, BTSG, HQY, WAY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
3.17 | 7.37M | 75,700 | -7.23M | -7.37M | -17.21 |
VEEV
Veeva Systems Inc
|
159.09 | 24.73B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
49.53 | 7.70B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
46.04 | 8.71B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
81.36 | 6.59B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
22.43 | 4.12B | 1.10B | 112.09M | 283.19M | 0.6096 |
Aclarion Inc Borsa (ACON) Ultime notizie
Aclarion's AI Platform Nociscan Wins Pinnacle Award, Validating Approach to Chronic Low Back Pain Diagnosis - citybuzz -
Aclarion Receives Pinnacle Award for AI Innovation - Yahoo Finance
Aclarion (ACON) price target decreased by 69.57% to 7.14 - MSN
Take Profit: Will Opendoor Technologies Inc outperform the market in YEAR2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
Aclarion Announces Agreement with Weill Cornell Medicine - Bitget
Aclarion establishes agreement with Weill Cornell Medicine By Investing.com - Investing.com Australia
Aclarion Partners with Weill Cornell Medicine to Expand Nociscan Use in Spine Pain Research - citybuzz -
Aclarion establishes agreement with Weill Cornell Medicine - Investing.com
Weill Cornell spine study adds Aclarion tool for chronic back pain - Stock Titan
Trading Action: How does Aclarion Inc compare to its peers2026 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video - marketscreener.com
Aclarion says one London clinic has used its back-pain scan nearly 100 times - Stock Titan
Why Aclarion Inc. stock could rally in 20262026 Short Interest & Verified Stock Trade Ideas - bollywoodhelpline.com
Aclarion (ACON) to Release Quarterly Earnings on Tuesday - Defense World
Chipmakers Recap: Will Aclarion Inc Equity Warrant outperform tech stocksMarket Activity Report & Expert Verified Movement Alerts - baoquankhu1.vn
Street Watch: Will Aclarion Inc Equity Warrant outperform tech stocksGap Up & Low Risk Investment Opportunities - baoquankhu1.vn
Aclarion (NASDAQ: ACON) seeks stockholder approval to expand equity plan to 500,000 shares - Stock Titan
ACON Should I Buy - Intellectia AI
Aclarion Inc Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - Mint
US Market Wrap: Will Aclarion Inc Equity Warrant outperform tech stocks2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Is Aclarion Inc Equity Warrant stock a good dividend stock2026 Momentum & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Macro: How does Aclarion Inc Equity Warrant correlate with Nasdaq2026 Growth vs Value & Fast Moving Stock Watchlists - baoquankhu1.vn
SEG Opportunity Fund (ACON) discloses 244,043 shares, 9.98% of Aclarion - Stock Titan
Aclarion (ACON): Analyst Lowers Price Target While Maintaining B - GuruFocus
Macro Review: Should I hold or sell Aclarion Inc Equity Warrant now2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. - Bitget
Investment Review: Is Aclarion Inc. still a buy after recent gains2026 Review & Stepwise Trade Signal Guides - baoquankhu1.vn
Targets Report: Is Aclarion Inc still a buy after recent gainsPortfolio Update Summary & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Aclarion, Inc. Adopts One-Year Stockholder Rights Plan to Protect Shareholder Value and Prevent Hostile Takeovers - Minichart
Aclarion adopts one-year stockholder rights plan By Investing.com - Investing.com India
Aclarion Adopts One-Year Stockholder Rights Protection Plan - TipRanks
Aclarion (NASDAQ: ACON) sets 10% trigger in one-year rights plan - Stock Titan
Aclarion adopts one-year stockholder rights plan - Investing.com
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan - The Manila Times
Aclarion installs 1-year takeover defense, keeps door open to fair bids - Stock Titan
Shareholder Letter From Chief Executive Officer Brent Ness - 富途牛牛
Aclarion, Inc. Pursues Insurance Reimbursement Initiatives and Reports Strong Momentum Leading into 2026 - Quiver Quantitative
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts - Bluefield Daily Telegraph
Aclarion : Shareholder Letter from Chief Executive Officer Brent Ness - MarketScreener
Aclarion, Inc. Revolutionizes Low Back Pain Diagnosis with MR Spectroscopy and AI-Powered NOCISCAN Platform 798083 - Minichart
Published on: 2026-03-19 07:53:44 - baoquankhu1.vn
Aclarion (NASDAQ: ACON) expands NOCISCAN spine diagnostics and AI plans - Stock Titan
Aclarion 10-K: Revenue $0.076M, EPS (13.61) — Annual Report Highlights - tradingview.com
ACON: Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026 - tradingview.com
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-03-19 06:54:42 - baoquankhu1.vn
Aclarion to Present at ROTH Conference, Showcasing Nociscan Technology for Chronic Back Pain Diagnosis - citybuzz -
Is Aclarion Inc Equity Warrant still a buy after recent gainsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Aclarion, Inc. to Engage with Investors at the 38th Annual ROTH Conference Regarding Nociscan Advancements - Quiver Quantitative
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet - Bitget
Aclarion Inc Azioni (ACON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):